July 32, 2025 -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), today announced the US Food and Drug Administration (“FDA”) approved VIZZ (aceclidine ophthalmic solution) 2.44%, the first and only FDA……
July 24, 2025 -- Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved finerenone (Kerendia™), a non-steroidal, selective mineralocorticoid receptor antagonist, for the treatment of adult pa……
On June 24, 2025, PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that Sephience™ (sepiapterin) was granted marketing authorization by the European Commission for the treatment of children and adults living wi……
On June 23, 2025, Nuvation Bio Inc. (NYSE: NUVB) announced that the U.S. Food and Drug Administration (FDA) has approved IBTROZI™ (taletrectinib) for the treatment of adult patients with locally advanced or metastatic RO……
May 28, 2025 -- Alcon announced that the FDA has approved Tryptyr (acoltremon ophthalmic solution) 0.003%, for the treatment of the signs and symptoms of dry eye disease (DED). Tryptyr is a first - in - class TRPM8 recep……
May 22, 2025 -- U.S. President Donald Trump on Monday signed a sweeping executive order promising to target "unreasonable or discriminatory" practices by foreign countries that result in Americans paying more for prescri……
Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 苏ICP备12056923号-1
Tel: 025-82232955 025-82232966
Fax:025-82232933 025-82232944
E-mail: info@dorrapharma.com
